VYNE
VYNE Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.
Market Cap: 33.1 Million
Primary Exchange: NASDAQ
Shares Outstanding: 14.1 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.6076567636558033
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Ethical Flags
Longest drawdown: 221 trading days
From: 2023-05-08 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|